Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 8:33 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 433–454 of 454 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Amyotrophic Lateral Sclerosis(ALS) Clear all

Conditions: ALS (Amyotrophic Lateral Sclerosis)
Interventions: BCI Device; Device
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 18 Years to 79 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 5
States / cities: West Haven, Connecticut • Albany, New York • Durham, North Carolina + 2 more

Conditions: Frontotemporal Lobar Degeneration (FTLD), Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD), Behavioral Variant Frontotemporal Dementia (bvFTD), Semantic Variant Primary Progressive Aphasia (svPPA), Nonfluent Variant Primary Progressive Aphasia (nfvPPA), FTD With Amyotrophic Lateral Sclerosis (FTD/ALS), Amyotrophic Lateral Sclerosis, Oligosymptomatic PSP (oPSP), C9orf72, GRN Related Frontotemporal Dementia, MAPT Gene Mutation, TBK1 Gene Mutation, Oligosymptomatic Progressive Supranuclear Palsy
Interventions: Not listed
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 2,100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2030
U.S. locations: 24
States / cities: Birmingham, Alabama • Los Angeles, California • San Diego, California + 20 more

Conditions: ALS
Interventions: Not listed
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 99 Years
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Amyotrophic Lateral Sclerosis (ALS)
Interventions: Nurown MSC-NTF cells, Placebo; Biological
Lead sponsor: Brainstorm-Cell Therapeutics; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 3
States / cities: Boston, Massachusetts • Worcester, Massachusetts • Rochester, Minnesota

Conditions: Amyotrophic Lateral Sclerosis (ALS), Myasthenia Gravis, Myopathies, Stroke, Parkinson's Disease
Interventions: Not listed
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 20 Years to 90 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Amyotrophic Lateral Sclerosis
Interventions: AMX0035; Drug
Lead sponsor: Amylyx Pharmaceuticals Inc.; Industry
Eligibility: 18 Years and older
U.S. locations: 20
States / cities: Los Angeles, California • Oakland, California • Fort Lauderdale, Florida + 14 more

Conditions: Amyotrophic Lateral Sclerosis
Interventions: ALZT-OP1a (cromolyn); Drug
Lead sponsor: AZTherapies, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 6
States / cities: La Jolla, California • Jacksonville, Florida • New York, New York + 2 more

Conditions: Amyotrophic Lateral Sclerosis, Neurodegenerative Disease, Motor Neuron Disease
Interventions: Not listed
Lead sponsor: Drexel University College of Medicine; Other
Eligibility: 18 Years to 89 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Amyotrophic Lateral Sclerosis
Interventions: NP001, Placebo; Drug
Lead sponsor: Neuraltus Pharmaceuticals, Inc.; Industry
Eligibility: 21 Years to 80 Years
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 17
States / cities: Scottsdale, Arizona • Irvine, California • Los Angeles, California + 14 more

Conditions: Healthy Volunteers, Amyotrophic Lateral Sclerosis
Interventions: [18F]PBR06; Drug
Lead sponsor: Molecular NeuroImaging; Other
Eligibility: 18 Years to 80 Years
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Adjustment Disorder
Interventions: RE104 for Injection; Drug
Lead sponsor: Reunion Neuroscience Inc; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 32
States / cities: Birmingham, Alabama • Tucson, Arizona • San Diego, California + 28 more

Conditions: Amyotrophic Lateral Sclerosis (ALS)
Interventions: Intramuscular diaphragm electrodes; Device
Lead sponsor: Synapse Biomedical; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2009
U.S. locations: 7
States / cities: San Francisco, California • Stanford, California • Jacksonville, Florida + 4 more

Conditions: Amyotrophic Lateral Sclerosis (ALS)
Interventions: NurOwn® (MSC-NTF cells), Placebo, Bone Marrow aspiration; Biological · Other
Lead sponsor: Brainstorm-Cell Therapeutics; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 196 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 6
States / cities: Irvine, California • Los Angeles, California • San Francisco, California + 3 more

Conditions: Amyotrophic Lateral Sclerosis
Interventions: Acthar, Placebo; Drug
Lead sponsor: Mallinckrodt; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 143 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 39
States / cities: Phoenix, Arizona • Scottsdale, Arizona • La Jolla, California + 33 more

Conditions: Amyotrophic Lateral Sclerosis
Interventions: Dexpramipexole, Dexpramipexole Placebo, Moxifloxacin; Drug
Lead sponsor: Knopp Biosciences; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 68 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Spinal Muscular Atrophy, Charcot-Marie-Tooth Disease, Muscular Dystrophy, Spinal Muscular Atrophy With Respiratory Distress 1, Amyotrophic Lateral Sclerosis, Motor Neuron Disease, Neuromuscular Disease, Peroneal Muscular Atrophy
Interventions: sample collection; Other
Lead sponsor: Nemours Children's Clinic; Other
Eligibility: 1 Month and older
Enrollment: 230 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2024
U.S. locations: 3
States / cities: Wilmington, Delaware • Jacksonville, Florida • Orlando, Florida

Conditions: Amyotrophic Lateral Sclerosis
Interventions: Clenbuterol; Drug
Lead sponsor: Dwight Koeberl, M.D., Ph.D.; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Amyotrophic Lateral Sclerosis ALS
Interventions: β-hydroxy-β-methylbutyrate (HMB); Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: Durham, North Carolina • Philadelphia, Pennsylvania

Conditions: Amyotrophic Lateral Sclerosis (ALS)
Interventions: NUZ-001, Matching placebo; Drug
Lead sponsor: Merit E. Cudkowicz, MD; Other
Eligibility: 18 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Amyotrophic Lateral Sclerosis (ALS), Emotional Distress
Interventions: Resilient Together ALS; Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Amyotrophic Lateral Sclerosis
Interventions: Exercise; Procedure
Lead sponsor: University of Saskatchewan; Other
Eligibility: 18 Years to 80 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2004
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: ALS
Interventions: Riluzole Oral Soluble Film; Drug
Lead sponsor: Aquestive Therapeutics; Industry
Eligibility: 18 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: Dallas, Texas

Search by objective public record fields.

A Clinical Demonstration of EEG Brain-computer Interface for ALS Patients

ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)

Analysis of Post-Translational Modifications of a Critical Protein Implicated in Amyotrophic Lateral Sclerosis

Phase 2, Randomized, Double Blind, Placebo Controlled Multicenter Study of Autologous MSC-NTF Cells in Patients With ALS

Innovative Measures of Speech and Swallowing Dysfunction in Neurological Disorders

An Intermediate Size Expanded Access Protocol of AMX0035 for ALS

A Safety and Biomarker Study of ALZT-OP1a in Subjects With Mild-Moderate ALS Disease

Comparing The Cyberlink Control System to the Manual Letter Board for Communication Purposes in the ALS Patient Population

A Study of NP001 in Subjects With Amyotrophic Lateral Sclerosis (ALS)

Evaluation of Microglial Activation in ALS With [18F]PBR06 (Peripheral Benzodiazepine Receptor-06) PET

RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses

Motor-Point Stimulation for Conditioning the Diaphragm of Patients With Amyotrophic Lateral Sclerosis (ALS)

Safety and Efficacy of Repeated Administrations of NurOwn® in ALS Patients

Study of Acthar® Gel (Acthar) for Amyotrophic Lateral Sclerosis (ALS)

Study to Evaluate the QTC Interval in Healthy Volunteers Dosed With Dexpramipexole (QTC = Electrocardiogram (ECG) Interval Measured From the Onset of the QRS Complex to the End of the T Wave Corrected for Heart Rate)

Genetics of Pediatric-Onset Motor Neuron and Neuromuscular Diseases

Clenbuterol on Motor Function in Individuals With Amyotrophic Lateral Sclerosis

Pilot Trial Utilizing β-hydroxy-β-methylbutyrate to Lower IGFBP7 Levels in People With ALS

HEALEY ALS Platform Trial - Regimen I NUZ-001

Resiliency Intervention for Patients With ALS and Their Care-Partners

Study of the Effects Strengthening Exercises in Individuals With ALS

Riluzole Oral Soluble Film Safety and Tolerability in Amyotrophic Lateral Sclerosis